Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | ![]() CIMS Introduces AI-powered eBinder for auto-processing of clinical site data into EDC systemsCIMS Global unveils groundbreaking AI powered technology for Clinical Trials
By: CIMS Global eBinder eliminates the need for clinical site staff to manually enter patient data by transforming scanned paper Data Collection Forms (DCFs) into a digitally readable format for use in Electronic Data Capture (EDC) solutions. Downstream, a Clinical Research Associate (CRA) verifies data accuracy remotely, without having to physically be at the clinical site. This innovative technology could save thousands of hours in manual labor, and millions of dollars in on-site SDV (~25% of a typical trial budget). Most importantly, eBinder can significantly improve data quality and trial efficiency. "Despite the move to modern technology and applications over the years, a high percentage of clinical sites still record patient's clinical trial data on paper," says Tai Xie, Ph.D., Founder and CEO of CIMS Global. "Clinical staff manually enter that paper data into an EDC system which is very time consuming and prone to transcription errors. That data then must be verified by a CRA on-site to ensure its accuracy which adds another labor-intensive step. eBinder eliminates these manual data entry processes by leveraging an AI engine to automate and accurately complete these operations. We are thrilled to launch this innovation onto the market, contributing to the transformation of the future of clinical trials – a vision that lies at the core of our company's foundation." eBinder:
Visit us at the SCOPE in Orlando, FL from February 12th -14th at booth #429. About CIMS Global With over 16 years of industry experience, CIMS Global has pioneered the approach of reshaping clinical trials with novel technology to streamline and create faster pathways to life-saving therapies. CIMS bridges the gap between researchers and effective treatments with significant cost-savings, speed and reliable data powered by a comprehensive platform. AI and machine learning unlock hidden insights, optimize trial design, and allow for faster, data-driven decisions. This integrated ecosystem connects every step of the trial, enabling real-time monitoring, proactive safety adjustments, and dynamic course correction. CIMS primary focus lies in creating novel tools that accelerate breakthroughs, enabling more drugs to reach the market faster, improving patient outcomes. End
|
|